Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Renalytix PLC on Monday said it expanded its insurance coverage base in the Northeast region of the US via a coverage contract with EmblemHealth, a non-profit health insurer with three million customers in the New York Tri-state area.
The London-based kidney health-focused diagnostics company said the contract builds on the comprehensive insurance coverage portfolio necessary to transition to a full commercial payment model for KidneyIntelX prognostic testing in New York state and Connecticut state.
Renalytix shares were 2.5% higher at 82.00 pence each in London on Monday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.